Genentech announced new, four-year data from the RHONE-X extension study. The study met all primary endpoints, showing that Vabysmo®? (faricimab-svoa) was well tolerated in people with diabetic macular edema (DME) who received treatment for up to four years.

Exploratory results from the long-term study showed that Vabysmo continued to preserve vision, dry retinal fluid that can impair sight and allow extended time between treatments in people with DME. These data were presented in a late-breaking oral presentation at the American Society of Retina Specialists (ASRS) 2024 Annual Meeting in Stockholm, Sweden. During RHONE-X, all participants were treated with Vabysmo on a personalized treat-and-extend regimen, where the time between Vabysmo treatments could be increased based on retinal fluid levels and visual acuity.

Results of the exploratory analysis showed that at the end of four years nearly 80% of participants treated with Vabysmo had extended their treatment intervals to every three or four months. It is also approved in several countries, including the United States (U.S.) and Japan, for the treatment of macular edema following retinal vein occlusion. More than four million doses of Vabysmo have been distributed worldwide since its initial U.S. approval in 2022.

Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Vabysmo to help minimize barriers to access and reimbursement. Patients can call 8833-EYE-GENE for more information. For people who qualify, Genentech offers patient assistance programs through Genentech Access Solutions.

More information is also available at (866) 4ACCESS =866) 422-2377.